What is StageBio's Revenue?
StageBio's estimated revenue for 2024 is $3.48M.
What does StageBio do?
StageBio is a leading international provider of GLP-compliant research, preclinical and clinical histology, pathology and specimen archiving services for the biopharmaceutical, medical device and contract research industries.
Formed through the merger of Histo-Scientific Research Laboratories (HSRL), Vet Path Services, Inc. (VPS), Tox Path Specialists (TPS), and Alizée Pathology, StageBio represents the combined capabilities of the most well-respected sources of high-quality histology and histopathology services in the preclinical and clinical research and development market.
Our acquisition in 2020 of TPL Path Labs of Freiburg, Germany, expanded our resources and our ability to researchers on both sides of the Atlantic. This advanced our global strategy to support researchers with the broadest range of solutions at every stage—from discovery through clinical development.
StageBio's integrated offering includes tissue analysis, efficacy determination for new compounds and devices, toxicological evaluation of products subject to regulatory approval, detailed pathology reporting for GLP studies, medical device pathology, immunohistochemistry, and neuropathology.
The company operates eight state-of-the-art sites in the U.S. and one facility in Germany, serving customers across the Americas, Europe, Australia, and Asia. We continue to make substantial investments in our facility and technology infrastructure to meet the growing demand for high-quality histopathology services.
At StageBio we have a team of board-certified veterinary pathologists and more than 75 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity and client satisfaction.
